A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

August 23, 2021

Primary Completion Date

September 8, 2021

Study Completion Date

September 8, 2021

Conditions
Pain
Interventions
DRUG

New Paracetamol Oral Suspension (24 mg/ml)

After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.

DRUG

Panadol B&I Oral Suspension (24 mg/ml paracetamol)

After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.

Trial Locations (1)

102 00

GSK Investigational Site, Prague

All Listed Sponsors
lead

HALEON

INDUSTRY

NCT05022810 - A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter